<DOC>
	<DOCNO>NCT00329368</DOCNO>
	<brief_summary>This Phase 1b clinical trial ass safety tolerability vaccination EC90 ( KLH-FITC ) GPI-0100 ( adjuvant ) follow treatment EC17 ( Folate-FITC ) combination low-dose cytokine ( IL-2 IFN-alpha ) patient metastatic refractory cancer .</brief_summary>
	<brief_title>Safety Tolerability Study FolateImmune Combination With Cytokines Patients With Refractory Metastatic Cancer</brief_title>
	<detailed_description>Rationale : This Phase 1b , single-cohort study FolateImmune combination low-doses cytokine Interleukin-2 ( IL-2 ) Interferon-alpha ( IFN-alpha ) . FolateImmune treatment consist subcutaneous vaccination EC90 , compound design elicit immune response ( antibody ) dye call fluorescein ( FITC ) , combination GPI-0100 adjuvant ( drug intend improve antibody production ) . Vaccination follow treatment EC17 , drug make link folate ( vitamin ) FITC . Experimental evidence show folate vitamin receptor over-expressed many human cancer . It expect EC17 attach cancer cell folate vitamin receptor antibody FITC recognize cancer cell mark destruction body 's immune system . Two drug , IL-2 IFN-alpha , administer low dos combination EC17 order boost immune response . Objectives : - Evaluate safety administer EC90 vaccine GPI-0100 adjuvant . - Evaluate safety administer EC17 concurrent IL-2 IFN-alpha</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Keyhole-limpet hemocyanin</mesh_term>
	<criteria>Have histologically confirm diagnosis metastatic refractory cancer effective standard therapeutic option available , ( Note : patient accrue Southern Illinois University , diagnosis renal ( i.e. , kidney ) carcinoma require . ) Have sign Institutional Review Board ( IRB ) approve informed consent form ( ICF ) prior perform study evaluation/procedures Be &gt; = 18 year age woman must either 1 ) childbearing potential 2 ) negative serum pregnancy test within 7 day prior commence treatment . Patients consider childbearing potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal ( 12 consecutive month amenorrhea [ lack menstruation ] ) ( If applicable ) Have complete prior cytotoxic chemotherapy , radiotherapy immunotherapy experimental therapy &gt; = 30 day prior study enrollment , recover form associate toxicity Have Eastern Cooperative Oncology Group ( ECOG ) score &lt; = 2 , anticipate life expectancy least 6 month Have adequate hematologic function , define absolute calculated neutrophil count &gt; = 1500/microL , platelet count &gt; = 100000/microL , lymphocyte count &gt; = 500/microL , hemoglobin level &gt; = 10 g/dL . Patients may receive prophylactic transfusion order qualify trial eligibility Have adequate renal function , define document serum creatinine &lt; = 2.0mg/dL . Greater `` 1+ '' proteinuria require microscope evaluation result discuss medical monitor prior patient enrollment ; serum creatine &gt; 2.0 , patient must actual calculate 24hour creatinine clearance &gt; 60mL/min obvious evidence concurrent medullary cystic disease obstructive uropathy Have adequate hepatic function , define total bilirubin level &lt; = 1.5 x upper limit normal ( ULN ) alkaline phosphatase , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) level &lt; = 2.5 x ULN . If alkaline phosphatase outside parameter due bone metastasis ( verified assessment isoenzymes ) , patient eligible . Have previously participate FolateImmune trial Have history severe hypersensitivity ( grade 3 4 allergic reaction ) fluorescein drug , radiologic contrast agent , insect bite , food , cytokine , agent ; receive fluorescein within 30 day study . Have medical condition preclude use IL2 IFNalpha . These condition include limited , diabetes mellitus history progression diabetic ketoacidosis , history severe coagulation disorder , psoriasis , sarcoidosis , retinal hemorrhage , symptomatic pulmonary disease , heart failure ( &gt; = New York Heart Association NYHA class II ) , transplant require immunosuppressive therapy Be pregnant breastfeed Be currently receive experimental drug , use experimental device within 30 day study entry Be currently undergo chemotherapy , anticancer hormonal therapy , and/or therapy immunosuppressant agent Have concomitant malignancy exception basal cell squamous cell carcinoma skin Have radiographically document evidence current brain metastasis , history stem cell transplant , immunodeficiency , and/or medical psychiatric illness ( investigator 's opinion , would prevent adequate compliance study therapy evaluation endpoint )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Phase I</keyword>
	<keyword>FolateImmune</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Refractory</keyword>
	<keyword>Experimental</keyword>
</DOC>